Intercept Pharmaceuticals

Intercept Pharmaceuticals EBIT Margin

Delisted

The EBIT Margin (Operating Margin) of Intercept Pharmaceuticals (ICPT) as of Oct 19, 2026 is -23.88 %. In the previous year, EBIT Margin (Operating Margin) was -15.34 % — a change of 55.64% (lower).

EBIT Margin

-23.88 %

YoY

55.64%

Last updated:

EBIT Margin (Operating Margin) of Intercept Pharmaceuticals is 2022 -23.88 % . EBIT Margin (Operating Margin) of Intercept Pharmaceuticals was 2021 -15.34 % . It decreases by 55.64% lower compared to the previous year.

For Intercept Pharmaceuticals, the operating (EBIT) margin of -23.9% is up versus -157.6% a few years ago.

The Intercept Pharmaceuticals EBIT Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT Margin
Date
EBIT Margin
Jan 1, 2015
-8,237.10 USD
Jan 1, 2016
-1,613.02 USD
Jan 1, 2017
-256.34 USD
Jan 1, 2018
-157.56 USD
Jan 1, 2019
-123.98 USD
Jan 1, 2020
-69.27 USD
Jan 1, 2021
-15.34 USD
Jan 1, 2022
-23.88 USD
The Intercept Pharmaceuticals EBIT Margin history
YEAREBIT MarginYoY
-23.88 %+55.64%
-15.34 %-77.85%
-69.27 %-44.12%
-123.98 %-21.31%
-157.56 %-38.54%
-256.34 %-84.11%
-1,613.02 %-80.42%
-8,237.10 %+26.79%
-6,496.56 %+26,603.50%
-24.33 %+214.63%
-7.73 %-6.17%
-8.24 %-75.36%
-33.44 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Intercept Pharmaceuticals Stock analysis

What does Intercept Pharmaceuticals do? Intercept Pharmaceuticals Inc is a biotechnology company based in New York City that focuses on the discovery and development of therapeutics for the treatment of chronic liver diseases. The company was founded in 2002 and has since brought a variety of innovative drugs to the market. The business model of Intercept Pharmaceuticals Inc is based on the invention, development, and marketing of drugs that specifically target certain disease conditions. They primarily focus on the development of drugs for the treatment of non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH). These two diseases are prevalent worldwide and pose significant health problems in many Western societies. Intercept Pharmaceuticals Inc has already achieved significant success in the treatment of NAFLD and NASH. The various divisions of Intercept Pharmaceuticals Inc can be divided into research, development of new products, sale of existing drugs, and collaboration with partners and other companies. In research, the company strives to develop the most effective and safe medications, utilizing state-of-the-art technologies and research methods. The main products of Intercept Pharmaceuticals Inc are Ocaliva and obeticholic acid. Ocaliva is a medication used to treat primary biliary cholangitis, a disease that causes inadequate movement of bile through the liver and its accumulation in the body. Ocaliva helps improve bile production and alleviate the symptoms of this disease. Obeticholic acid is a new approach to the treatment of NASH and is currently being tested in clinical trials. Intercept Pharmaceuticals Inc works closely with other companies and organizations to ensure the most effective therapy for patients worldwide. Interaction with industry colleagues, scientific institutions, and experts in the field of medical research allows for faster development of new products that benefit patients. Overall, Intercept Pharmaceuticals Inc has achieved an impressive track record in recent years. The company has established a strong position in the field of liver diseases by advancing research and development in innovative ways. The focus on NAFLD and NASH allows Intercept Pharmaceuticals Inc to play a leading role in this market segment and provide patients with effective medications for their conditions. In summary, Intercept Pharmaceuticals Inc is a company dedicated to the development and marketing of products for the treatment of liver diseases. Through the use of innovative technologies and close collaboration with other companies and organizations, Intercept Pharmaceuticals Inc has already achieved significant success in the development of new medications. The company has established a strong position in this market segment and aims to develop further innovative products to combat liver diseases in the future. Intercept Pharmaceuticals is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Intercept Pharmaceuticals stock

EBIT Margin (Operating Margin) of Intercept Pharmaceuticals is -23.88 % in 2022.

EBIT Margin (Operating Margin) of Intercept Pharmaceuticals changed from -15.34 % to -23.88 %, representing a 55.64% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EBIT Margin (Operating Margin) Intercept Pharmaceuticals since 2006 – with annual values, charts, and detailed analysis.

EBIT Margin measures operating profitability as a percentage of revenue. It shows how much profit a company makes from operations before interest and taxes.

A 'good' varies by industry and company stage. On Eulerpool, you can compare EBIT Margin (Operating Margin)'s Intercept Pharmaceuticals with sector peers and the industry average to assess whether it is attractive.

To evaluate EBIT Margin (Operating Margin)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EBIT Margin (Operating Margin).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Margins — Intercept Pharmaceuticals

Gross MarginEBIT MarginEBITDA MarginNet MarginFCF MarginR&D / RevenueTax RatePayout RatioPre-Tax MarginOCF MarginSGA/RevenueOpEx/RevenueReinvestment Rate

All Key Metrics — Intercept Pharmaceuticals